このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

LLM Intervention for Tobacco in Underserved Populations (LIFT-UP) (LIFT-UP)

2026年5月26日 更新者:University of Utah

This study will test a tailored, multilingual tobacco cessation chatbot called LIFT-UP (LLM Intervention for Tobacco in Underserved Populations), designed to better meet the needs of people living in persistent poverty census tracts.

We will use 1:1 semi-structured interviews to explore social drivers of health impacting TC, as well as digital access and preferences among those living in PPCTs. This qualitative approach enables guided yet flexible exploration of key domains while capturing unanticipated insights relevant to refining the chatbot.

調査の概要

状態

まだ募集していません

条件

詳細な説明

Tobacco use is a major cause of cancer and is responsible for about half a million deaths in the United States each year. Because of this, helping people stop using tobacco is one of the most important ways to prevent cancer. Although tobacco use has decreased over time, many adults in the U.S. still use tobacco. Many people try to quit each year, but most quit attempts are not successful. One reason is that many people do not use proven, evidence-based quit support, such as counseling or quit medications.

People who live in areas with long-term poverty often face additional barriers that can make quitting harder. These areas may have fewer job and education opportunities, limited access to healthcare and community resources, and higher levels of day-to-day stress (for example, related to financial strain or lack of health insurance). People with lower income are just as likely to try to quit as those with higher income, but they are less likely to quit successfully and are less likely to use evidence-based quitting support. Many persistent poverty areas are also rural and have higher numbers of people who prefer to speak languages other than English, including Spanish, which creates an additional need for bilingual and culturally appropriate quit support.

Digital tools may help increase access to evidence-based tobacco cessation support in these communities. Mobile phone ownership is very common, including among people with lower incomes. However, some smartphone apps require reliable internet access or data plans, which can be a barrier. Text messaging is accessible on nearly all phones, does not require internet access, can be offered in multiple languages, and can be tailored to the needs of the user.

Text-based programs that use artificial intelligence (AI), such as large-language-model chatbots, may be especially useful because they can provide interactive support using natural language and can be delivered at scale. Chatbots have been used successfully in other areas of health, but many existing programs use fixed scripts and may not feel relevant or helpful for all groups. Importantly, most tobacco cessation chatbots have not been designed to address barriers faced by people living in persistent poverty areas.

研究の種類

介入

入学 (推定)

22

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Utah
      • Salt Lake City、Utah、アメリカ、84102
        • Huntsman Cancer Institute/ University of Utah
        • コンタクト:
        • 主任研究者:
          • Lindsey Potter, MPH, PhD
        • 主任研究者:
          • Christian Mahony Reategui Rivera, MD, MS

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • 18+ years old
  • Use ≥3 cigarettes/day on average
  • Motivated to quit in the next 30 days
  • Have a computer or tablet with internet access for 1:1 interviews
  • Speak English or Spanish
  • Home address is in an area characterized by persistent poverty

Exclusion Criteria:

  • None

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Moderated Session
Participants will attend a ~80 minute moderated "think-aloud" session via HIPAA compliant videoconferencing platform.
LIFT-UP Chatbot will be developed, evaluated, and refined using GARDE-Chat, an open-source chatbot authoring platform that has been used to support the development of chatbot-based interventions tested in large pragmatic clinical trials.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
System Usability Scale (SUS)
時間枠:up to 1 day

Usability will be measured using the SUS, a questionnaire assessing the perceived usability of a system, product, website, app, or digital intervention. It consists of ten 5-point Likert items ranging from "Strongly disagree" to "Strongly agree".

Scoring follows the standard SUS scoring procedure, for positively worded items, the item score is calculated as response minus 1; for negatively worded items, the item score is calculated as 5 minus the response. The 10 item scores are summed and then multiplied by 2.5 to generate the final SUS score, with higher scores indicating greater perceived usability. Score range: 0-100.

up to 1 day

二次結果の測定

結果測定
メジャーの説明
時間枠
Usability - Chat Bot Usability Scale (BUS-11)
時間枠:up to 1 day
Chatbot usability will be measured using the Chatbot Usability Scale (BUS-11). BUS-11 is a measured that assesses users' experiences after interacting with a chatbot or conversational agent. The BUS-11 consists of eleven 5-point Likert items ranging from "Strongly disagree" to "Strongly agree". Each item is coded from 1 to 5, and item scores are summed to create a total score. Higher scores indicate greater perceived chatbot usability. Score range: 11-55.
up to 1 day
Acceptability
時間枠:up to 1 day
Acceptability will be measured using the Acceptability of Intervention Measure (AIM). AIM is an instrument that assesses the perceived acceptability of an intervention. It consists of four 5 point Likert items ranging from "Completely "disagree" to "Strongly agree". Each item is coded from 1 to 5, and the overall score is the mean of the items score. Higher scores indicate greater perceived acceptability of the intervention. Score range: 1-5.
up to 1 day
Digital Working Alliance
時間枠:up to 1 day
Working alliance in the digital context will be measured with the Digital Working Alliance inventory (D-WAI). D-WAI is derived from the Working Alliance Inventory and measures the perceived working alliance (e.g., traditionally the collaborative bond between therapist and client) with digital interventions. It includes six 7-point Likert items ranging from "Strongly disagree" to "Strongly agree". Each item is coded from 1 to 7, and item scores are summed to create a total score. Higher scores indicate a stronger perceived digital working alliance. Score range: 7-42.
up to 1 day
Perceived cultural fit
時間枠:up to 1 day
Perceived cultural relevance will be measured using the Cultural Relevance Questionnaire (CRQ). CRQ consists of six 5-point Likert items ranging from "Strongly disagree" to "Strongly agree. Higher scores indicate greater perceived cultural appropriateness/relevance of the intervention. Score range: 5-25. An additional 5-point Likert-like question was added to reflect overall cultural fit perceived by the users.
up to 1 day

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Chelsey Schlechter, MPH, PhD、Huntsman Cancer Institute/ University of Utah
  • 主任研究者:Christian Mahony Reategui Rivera, MD, MS、University of Utah

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2027年5月31日

研究の完了 (推定)

2027年5月31日

試験登録日

最初に提出

2026年5月26日

QC基準を満たした最初の提出物

2026年5月26日

最初の投稿 (実際)

2026年6月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月2日

QC基準を満たした最後の更新が送信されました

2026年5月26日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • HCI199440
  • U54CA280812 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

De-identified data will be shared with only with investigators that have a data sharing agreement through PIVOT.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

LIFT-UP Chatbotの臨床試験

購読する